What is the current status of Euroapi's Brindisi site and why was production halted?

Production at Euroapi's Brindisi site has been halted since March 2024 following an internal audit that identified quality-control deficiencies due to potential local misconduct at Euroapi Italy Srl. The site produces 11 APIs and intermediates, mostly anti-infectives including spiramycin, rifaximin, rifampicin and teicoplanin.

Is Euroapi committed to selling the Brindisi site, and what is the timeline for any potential decision?

Euroapi is engaged in discussions with potential buyers regarding the future of the Brindisi site, but no decision has been made yet. These discussions are part of the group’s FOCUS-27 transformation plan, which aims to complete related processes by the end of 2027.

Euroapi in discussions with potential buyers for Brindisi site in Italy

May 14, 2026

Euroapi SA is in discussions with potential buyers for its Brindisi site, which produces 11 APIs including anti-infectives. Production at the facility has been halted since March 2024 due to quality-control deficiencies.

chemweek

2026-05-14

Euroapi in discussions with potential buyers for Brindisi site in Italy

Euroapi in discussions with potential buyers for Brindisi site in Italy

FAQ